Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival
Treating individual metastatic tumors with highly focused radiation or surgery did not improve progression-free or overall survival for patients with oligometastatic breast cancer receiving first-line systemic therapy, according to results from the randomized NRG-BR002 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
